Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

By R. Thompson, Michael D. Gillett, John C. Cheville, Christine M. Lohse, Haidong Dong, W. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, Lieping Chen and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2004

620 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/be7804075b177556ec3d4a117b9a756eb1f2de8b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. Lieping Chen
3. Arlene H. Sharpe
4. G. Freeman
5. S. Topalian
6. B. Fife
7. J. Bluestone
8. Janis Taube

In Oncology

1. D. Pardoll
2. Lieping Chen
3. Arlene H. Sharpe
4. G. Freeman
5. S. Topalian
6. J. Bluestone
7. Janis Taube
8. B. Fife

Citations in the corpus

• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. (2014, neutral): “ciated with poor outcomes following chemoradiotherapy in cancer patients (27, 28).”
• Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy (2014, background): “Tumor expression of PD-L1 inhibits tumor-reactive T cells in animal models (6–8), and some clinical studies show correlations between tumor expression of PD-L1 and PD-L2 and adverse outcomes (9, 10).”
• Mechanisms controlling PD-L1 expression in cancer (2019, background): “In cancer cells, including renal cell carcinoma (RCC), and breast, colorectal, gastric, nonsmall cell lung (NSCLC), papillary thyroid, and testicular cancers (Thompson et al., 2004), high PD-L1 expression is detected and associated with poor prognosis (Ohaegbulam et al.”
• Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “However, this is not the case for all tumor types since, in different clinical trials, patients with kidney cancer, which has a relatively low mutational frequency, have had noticeable clinical responses to anti-PD1 treatment [159].”
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. (2006, background): “[22] have found a correlation between B7-H1 expression and lower survival rate among renal cell carcinoma patients.”
• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways (2008, background): “In fact, PD-1 expression levels have been shown to correlate with tumor prognosis; higher PD-1 levels are associated with poorer prognosis (146, 147).”
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (2009, background): “PD-L1 is expressed on a wide variety of tumors, and high levels of PD-L1 expression strongly correlate with unfavorable prognosis in several cancers (Dong et al., 2002; Iwai et al., 2002; Strome et al., 2003; Konishi et al., 2004; Thompson et al., 2004; Blank et al., 2005; Hirano et al., 2005; Ohiga”
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, background): “Additionally, expression of B7-H1 by TILs has been reported to correlate with decreased patient survival (27, 28), suggesting that B7-H1 expression in the tumor microenvironment may exert an immunosuppressive function.”